Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 6/2016

01-06-2016 | Original Article

Downregulation of SATB1 increases the invasiveness of Jurkat cell via activation of the WNT/β-catenin signaling pathway in vitro

Authors: Xiao-Dan Luo, Shao-Jiang Yang, Jia-Ni Wang, Li Tan, Dan Liu, Ya-Ya Wang, Run-Hui Zheng, Xiao-Hong Wu, Li-Hua Xu, Huo Tan

Published in: Tumor Biology | Issue 6/2016

Login to get access

Abstract

Special AT-rich sequence-binding protein-1 (SATB1) is critical for genome organizer that reprograms chromatin organization and transcription profiles, and associated with tumor growth and metastasis in several cancer types. Many studies suggest that SATB1 overexpression is an indicator of poor prognosis in various cancers, such as breast cancer, malignant cutaneous melanoma, and liver cancer. However, their expression patterns and function values for adult T cell leukemia (ATL) are still largely unknown. The aim of this study is to examine the levels of SATB1 in ATL and to explore its function and mechanisms in Jurkat cell line. Here, we reported that SATB1 expressions were decreased in ATL cells (p < 0.001) compared with normal controls. Knockdown of SATB1 expression significantly enhanced invasion of Jurkat cell in vitro. Furthermore, knockdown of SATB1 gene enhances β-catenin nuclear accumulation and transcriptional activity and thus may increase the invasiveness of Jurkat cell through the activation of Wnt/β-catenin signaling pathway in vitro.
Literature
1.
Chiaretti S, Gianfelici V, Ceglie G, Foa R. Genomic characterization of acute leukemias. Med Princ Pract. 2014;23(6):487–506.CrossRefPubMed
2.
Soyoral Y, Aslan M, Ebinc S, Dirik Y, Demir C. Life-threatening hypophosphatemia and/or phosphate depletion in a patient with acute lymphoblastic leukemia: a rare case report. Am J Emerg Med 2014. doi: 10.S0735-6757(14)00255-1.
3.
Zeng H, Wang XB, Cui NH, Nam S, Zeng T, Long X. Associations between AT-rich interactive domain 5B gene polymorphisms and risk of childhood acute lymphoblastic leukemia: a meta-analysis. Asian Pac J Cancer Prev. 2014;15(15):6211–7.CrossRefPubMed
4.
5.
Sabir N, Iqbal Z, Aleem A, Awan T, Naeem T, Asad S, et al. Prognostically significant fusion oncogenes in Pakistani patients with adult acute lymphoblastic leukemia and their association with disease biology and outcome. Asian Pac J Cancer Prev. 2012;13(7):3349–55.CrossRefPubMed
6.
Huang Y, Zhang L, Song NN, Hu ZL, Chen JY, Ding YQ. Distribution of Satb1 in the central nervous system of adult mice. Neurosci Res. 2011;71(1):12–21.CrossRefPubMed
7.
8.
Yasui D, Miyano M, Cai S, Varga-Weisz P, Kohwi-Shigematsu T. SATB1 targets chromatin remodelling to regulate genes over long distances. Nature. 2002;419(6907):641–5.CrossRefPubMed
9.
10.
Burute M, Gottimukkala K, Galande S. Chromatin organizer SATB1 is an important determinant of T-cell differentiation. Immunol Cell Biol. 2012;90(9):852–9.CrossRefPubMed
11.
Agrelo R, Souabni A, Novatchkova M, Haslinger C, Leeb M, Komnenovic V, et al. SATB1 defines the developmental context for gene silencing by Xist in lymphoma and embryonic cells. Dev Cell. 2009;16(4):507–16.CrossRefPubMedPubMedCentral
12.
Zhang Y, Tian X, Ji H, Guan X, Xu W, Dong B et al. Expression of SATB1 promotes the growth and metastasis of colorectal cancer. PLoS One. 2014;9(6).
13.
Zhang S, Gao X, Ma Y, Jiang J, Dai Z, Yin X, et al. Expression and significance of SATB1 in the development of breast cancer. Genet Mol Res. 2015;14(2):3309–17.CrossRefPubMed
14.
Liu X, Zheng Y, Qiao C, Qv F, Wang J, Ding B, et al. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics. Diagn Pathol. 2015;10:50.CrossRefPubMedPubMedCentral
15.
Niu Y, Wang L, Cheng C, Du C, Lu X, Wang G, et al. Increased expressions of SATB1 and S100A4 are associated with poor prognosis in human colorectal carcinoma. APMIS. 2014;123(2):93–101.CrossRefPubMed
16.
Hedner C, Gaber A, Korkocic D, Nodin B, Uhlen M, Kuteeva E, et al. SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma. Virchows Arch. 2014;465(6):649–59.CrossRefPubMedPubMedCentral
17.
Chen H, Takahara M, Oba J, Xie L, Chiba T, Takeuchi S, et al. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma. J Dermatol Sci. 2011;64(1):39–44.CrossRefPubMed
18.
Zhang L, Cheng F, He R, Chen H, Liu Y, Sun J. Inhibition of SATB1 by shRNA suppresses the proliferation of cutaneous malignant melanoma. Cancer Biother Radiopharm. 2014;29(2):77–82.CrossRefPubMedPubMedCentral
19.
Tu W, Luo M, Wang Z, Yan W, Xia Y, Deng H, et al. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int. 2012;32(7):1064–78.CrossRefPubMed
20.
Zhao XD, Ji WY, Zhang W, He LX, Yang J, Liang HJ, et al. Overexpression of SATB1 in laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 2010;72(1):1–5.CrossRefPubMed
21.
Xiang J, Zhou L, Li S, Xi X, Zhang J, Wang Y, et al. AT-rich sequence binding protein 1: contribution to tumor progression and metastasis of human ovarian carcinoma. Oncol Lett. 2012;3(4):865–70.PubMedPubMedCentral
22.
Nodin B, Hedner C, Uhlen M, Jirstrom K. Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer. J Ovarian Res. 2012;5(1):24.CrossRefPubMedPubMedCentral
23.
Selinger CI, Cooper WA, Al-Sohaily S, Mladenova DN, Pangon L, Kennedy CW, et al. Loss of special AT-rich binding protein 1 expression is a marker of poor survival in lung cancer. J Thorac Oncol. 2011;6(7):1179–89.CrossRefPubMed
24.
Wang Y, Su M, Zhou LL, Tu P, Zhang X, Jiang X, et al. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription. Blood. 2011;117(14):3826–35.CrossRefPubMed
25.
Ahlfors H, Limaye A, Elo LL, Tuomela S, Burute M, Gottimukkala KV, et al. SATB1 dictates expression of multiple genes including IL-5 involved in human T helper cell differentiation. Blood. 2010;116(9):1443–53.CrossRefPubMedPubMedCentral
26.
Notani D, Gottimukkala KP, Jayani RS, Limaye AS, Damle MV, Mehta S et al. Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol. 2010;8(1).
27.
Niu Z, Liu H, Zhou M, Wang H, Liu Y, Li X, et al. Knockdown of c-Myc inhibits cell proliferation by negatively regulating the Cdk/Rb/E2F pathway in nasopharyngeal carcinoma cells. Acta Biochim Biophys Sin (Shanghai). 2015;47(3):183–91.CrossRef
28.
Liu Z, He Q, Ding X, Zhao T, Zhao L, Wang A. SOD2 is a C-myc target gene that promotes the migration and invasion of tongue squamous cell carcinoma involving cancer stem-like cells. Int J Biochem Cell Biol. 2015;60:139–46.CrossRefPubMed
29.
Choi YL, Tsukasaki K, O’Neill MC, Yamada Y, Onimaru Y, Matsumoto K, et al. A genomic analysis of adult T-cell leukemia. Oncogene. 2007;26(8):1245–55.CrossRefPubMed
Metadata
Title
Downregulation of SATB1 increases the invasiveness of Jurkat cell via activation of the WNT/β-catenin signaling pathway in vitro
Authors
Xiao-Dan Luo
Shao-Jiang Yang
Jia-Ni Wang
Li Tan
Dan Liu
Ya-Ya Wang
Run-Hui Zheng
Xiao-Hong Wu
Li-Hua Xu
Huo Tan
Publication date
01-06-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 6/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4638-x

Other articles of this Issue 6/2016

Tumor Biology 6/2016 Go to the issue

Original Article

Inhibition of CXCR4 and CXCR7 for reduction of cell proliferation and invasion in human endometrial cancer

Original Article

The variation and clinical significance of hormone receptors and Her-2 status from primary to metastatic lesions in breast cancer patients

Original Article

Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells

Original Article

Immunomodulatory and cellular antioxidant activities of pure compounds from Teucrium ramosissimum Desf.

Original Article

Clinicopathological significance of p38β, p38γ, and p38δ and its biological roles in esophageal squamous cell carcinoma

Original Article

Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits